TY - JOUR
T1 - The potential of stem bark of kayu sarampa (Xylocarpus moluccensis (Lam.) M. Roen)) as α-glucosidase inhibitor
AU - Budiarso, Fitri Santy
AU - Elya, Berna
AU - Hanafi, Muhammad
AU - Forestrania, Roshamur Cahyan
N1 - Publisher Copyright:
© 2020 Phcogj.Com.
PY - 2020/12
Y1 - 2020/12
N2 - Introduction: The prevalence of diabetes mellitus type 2 in the world is more than 230 million people, increases about 3% in a year. Kayu Sarampa or Nyirih batu (Xylocarpus moluccensis (Lam.) M. Roen) has traditionally been used to treat diabetic patient by native people in Ratahan, North Celebes, Indonesia. Therefore, this research was sequentially extracted bioactive component from stem bark of kayu sarampa showed alpha glucosidase inhibitor. Objective: To assess antioxidants and alpha glucosidase inhibitory activity of hexane, ethyl acetate, and methanol extract from stem bark of Kayu Sarampa. Method: The Stem bark was extracted with Reflux method using hexane, ethyl acetate, and methanol as mobile phae/solvent. The Hexane Extract (HE), Ethyl Acetic Extract (EAE) and Methanol Extract (ME) were subjected to the antioxidant activity assay by the 2.2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging and the ferric-reducing antioxidant power (FRAP) method. Antidiabetic activity was determined by enzymatic alpha-glucosidase inhibitor. Results: The extract which had the highest activity based on the DPPH test and FRAP test was the ME compared with EAE, and HE with IC50 values of 16.51 μg/mL, 34.10 51 μg/mL, and 38.82 51 μg/mL, respectively. Ferrous equivalent antioxidant capacity (FeEAC) method, methanolic extract had a higher reduction capacity than the EH and EEA which were 148.96 μmol/gr, 48.96 μmol/gr, and 148.96 μmol/gr, respectively. The result showed that kayu sarampa stem bark exhibited antidiabetic activity due to its high inhibition compared with control (acarbose). ME showed inhibition of 53,11% followed with EAE 49,7%, HE 44,53%, and acarbose as control 29,32%.Conclusion: stem bark of kayu sarampa have bioactive component as alpha glucosidase inhibitor.
AB - Introduction: The prevalence of diabetes mellitus type 2 in the world is more than 230 million people, increases about 3% in a year. Kayu Sarampa or Nyirih batu (Xylocarpus moluccensis (Lam.) M. Roen) has traditionally been used to treat diabetic patient by native people in Ratahan, North Celebes, Indonesia. Therefore, this research was sequentially extracted bioactive component from stem bark of kayu sarampa showed alpha glucosidase inhibitor. Objective: To assess antioxidants and alpha glucosidase inhibitory activity of hexane, ethyl acetate, and methanol extract from stem bark of Kayu Sarampa. Method: The Stem bark was extracted with Reflux method using hexane, ethyl acetate, and methanol as mobile phae/solvent. The Hexane Extract (HE), Ethyl Acetic Extract (EAE) and Methanol Extract (ME) were subjected to the antioxidant activity assay by the 2.2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging and the ferric-reducing antioxidant power (FRAP) method. Antidiabetic activity was determined by enzymatic alpha-glucosidase inhibitor. Results: The extract which had the highest activity based on the DPPH test and FRAP test was the ME compared with EAE, and HE with IC50 values of 16.51 μg/mL, 34.10 51 μg/mL, and 38.82 51 μg/mL, respectively. Ferrous equivalent antioxidant capacity (FeEAC) method, methanolic extract had a higher reduction capacity than the EH and EEA which were 148.96 μmol/gr, 48.96 μmol/gr, and 148.96 μmol/gr, respectively. The result showed that kayu sarampa stem bark exhibited antidiabetic activity due to its high inhibition compared with control (acarbose). ME showed inhibition of 53,11% followed with EAE 49,7%, HE 44,53%, and acarbose as control 29,32%.Conclusion: stem bark of kayu sarampa have bioactive component as alpha glucosidase inhibitor.
KW - Alpha-glucosidase inhibitor
KW - Antidiabetic
KW - Antioxidant
KW - Kayu Sarampa
UR - http://www.scopus.com/inward/record.url?scp=85092229184&partnerID=8YFLogxK
U2 - 10.5530/PJ.2020.12.189
DO - 10.5530/PJ.2020.12.189
M3 - Article
AN - SCOPUS:85092229184
SN - 0975-3575
VL - 12
SP - 1368
EP - 1376
JO - Pharmacognosy Journal
JF - Pharmacognosy Journal
IS - 6
ER -